Skip to content
Sign in

IHE · ARCA · ETF

iShares U.S. Pharmaceutical ETF (IHE) Price, Holdings & Fees

$816.81−0.87%−$7.18End-of-day price as of Oct 9, 2026

iShares U.S. Pharmaceutical ETF (IHE) closed at $816.81 on Oct 9, 2026, down 0.87% from the previous close of $823.99.

Share price, past year

1Y −14.51%

52-week range $805.89 – $976.25. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$816.81
Sep 30, 2026$826.95
Aug 31, 2026$861.33
Jul 31, 2026$862.98
Jun 30, 2026$812.29
May 29, 2026$836.66
Apr 30, 2026$841.21
Mar 31, 2026$941.33
Feb 27, 2026$964.07
Jan 30, 2026$936.89
Dec 31, 2025$952.51
Nov 28, 2025$961.98
Oct 31, 2025$934.02

Key statistics

Expense ratio
0.38%
as of Mar 31, 2025
Net assets
$1.1B
as of Jun 30, 2026
Holdings
59
as of Jun 30, 2026
52-week range
$805.89 – $976.25

iShares U.S. Pharmaceutical ETF's expense ratio is 0.38%: $38.00 a year on $10,000 invested.

Holdings

iShares U.S. Pharmaceutical ETF held 59 investments worth $1.14B as of Jun 30, 2026. Its largest holding was JOHNSON & JOHNSON, at 22.44% of the fund.

iShares U.S. Pharmaceutical ETF largest holdings by share of net assets
#Holding% of fundValue
1JOHNSON & JOHNSON22.44%$255.48M
2ELI LILLY AND COMPANY22.25%$253.23M
3BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares6.24%$71.06M
4MERCK & CO., INC.4.55%$51.77M
5BRISTOL-MYERS SQUIBB COMPANY4.37%$49.73M
6ROYALTY PHARMA PLC4.34%$49.35M
7VIATRIS INC.4.22%$48.05M
8PFIZER INC.3.96%$45.13M
9ZOETIS INC.3.73%$42.42M
10JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY3.45%$39.28M
11ELANCO ANIMAL HEALTH INCORPORATED2.81%$31.94M
12AXSOME THERAPEUTICS, INC.2.41%$27.49M
13CORCEPT THERAPEUTICS INCORPORATED1.90%$21.58M
14LIGAND PHARMACEUTICALS INCORPORATED1.45%$16.46M
15Definium Therapeutics Inc1.39%$15.81M
16Liquidia Corp1.28%$14.55M
17INDIVIOR PHARMACEUTICALS, INC.1.14%$13.00M
18Crinetics Pharmaceuticals Inc0.90%$10.25M
19ORGANON & CO.0.81%$9.25M
20Edgewise Therapeutics Inc0.70%$7.96M
21AMNEAL PHARMACEUTICALS, INC.0.68%$7.76M
22Enliven Therapeutics Inc0.63%$7.18M
23SUPERNUS PHARMACEUTICALS, INC.0.62%$7.02M
24Tarsus Pharmaceuticals Inc0.57%$6.47M
25Veradermics Inc0.56%$6.40M

Top 25 of 59 holdings, as of Jun 30, 2026. Percentages are of the fund's net assets.

What the fund owns

iShares U.S. Pharmaceutical ETF holdings by asset type
Asset type% of fund
Stocks99.92%
Cash and short-term investments6.31%
iShares U.S. Pharmaceutical ETF holdings by country, largest 6
Country% of fund
United States96.39%
United Kingdom4.34%
Ireland3.78%
Canada1.39%
Singapore0.20%
Cayman Islands0.15%

Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.

Monthly total returns

Over the 3 months to Jun 30, 2026, iShares U.S. Pharmaceutical ETF's total return was +14.60%, as reported to the SEC.

iShares U.S. Pharmaceutical ETF monthly total returns
MonthTotal return
Jun 30, 2026+8.22%
May 31, 2026+4.71%
Apr 30, 2026+1.13%

The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.

Fund profile

Name
iShares U.S. Pharmaceutical ETF
Ticker
IHE
Exchange
ARCA
Fund type
ETF
Trust
iSHARES TRUST
SEC series ID
S000009417
SEC CIK
0001100663
Fractional shares
Yes

Recent SEC filings

Shareholder reports and prospectuses are filed by iSHARES TRUST, the trust behind iShares U.S. Pharmaceutical ETF, and cover all of its funds.

Frequently asked questions

What is IHE's price?

iShares U.S. Pharmaceutical ETF (IHE) closed at $816.81 on Oct 9, 2026, down 0.87% from the previous close of $823.99.

What is IHE's expense ratio?

iShares U.S. Pharmaceutical ETF's expense ratio is 0.38%: $38.00 a year on $10,000 invested.

What does IHE hold?

iShares U.S. Pharmaceutical ETF held 59 investments worth $1.14B as of Jun 30, 2026. Its largest holding was JOHNSON & JOHNSON, at 22.44% of the fund. Its five largest holdings were JOHNSON & JOHNSON, ELI LILLY AND COMPANY, BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares, MERCK & CO., INC., BRISTOL-MYERS SQUIBB COMPANY.

How has IHE performed?

Over the 3 months to Jun 30, 2026, iShares U.S. Pharmaceutical ETF's total return was +14.60%, as reported to the SEC.

Sources and methodology

Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jun 30, 2026 (filed Aug 24, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Mar 31, 2025. Prices are generated sample data for development. Data sources and disclosures